| Not Yet Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) NCT07496567 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) NCT07440225 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Not Yet Recruiting | Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization NCT07187804 | Kim's Eye Hospital | Phase 4 |
| Recruiting | Effect of Video Viewing on Intravitreal Injection Experience NCT07002372 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Not Yet Recruiting | An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings NCT06918028 | Zhongshan Ophthalmic Center, Sun Yat-sen University | — |
| Unknown | Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization NCT06243406 | Beijing Hospital | — |
| Completed | Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV NCT05662943 | Kim's Eye Hospital | — |
| Unknown | OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT. NCT05055973 | Assiut University | — |
| Completed | Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops NCT04782271 | Sylentis, S.A. | Phase 1 |
| Recruiting | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One NCT04704921 | AbbVie | Phase 2 / Phase 3 |
| Completed | Time Efficiency Comparison of Two IntraVitreal Injection Techniques NCT04455399 | Peregrine Eye and Laser Institute | N/A |
| Unknown | OCTA Metrics Repeatability and Reproducibility in Different Disorders NCT04488887 | Tanta University | — |
| Active Not Recruiting | Biomarkers and Choroidal Neovascularization NCT04439708 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Unknown | Imaging of the Angiofibrotic Switch in Neovascular AMD NCT03838679 | Medical University of Vienna | — |
| Unknown | Effect of Corona Virus on Intravitreal Injections NCT05494775 | Benha University | N/A |
| Terminated | Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related NCT03452527 | Iconic Therapeutics, Inc. | Phase 2 |
| Completed | Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovasculari NCT03793400 | Changhua Christian Hospital | — |
| Terminated | Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging NCT03105609 | Center for Eye Research Australia | — |
| Completed | Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid NCT04075188 | Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | N/A |
| Unknown | Conbercept in Choroidal Neovascularization Secondary to Uveitis NCT02934841 | Chongqing Medical University | Phase 2 |
| Completed | Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macul NCT02821247 | Bayer | — |
| Completed | Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of NCT03024424 | University of Utah | N/A |
| Terminated | Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated) NCT02857894 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Completed | A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Seco NCT02484690 | Hoffmann-La Roche | Phase 2 |
| Completed | Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 NCT02434328 | Alcon Research | Phase 3 |
| Completed | Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization NCT03042871 | Zhongshan Ophthalmic Center, Sun Yat-sen University | Phase 4 |
| Unknown | Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection NCT02486484 | Rafic Hariri University Hospital | Phase 2 |
| Completed | Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related NCT02358889 | Iconic Therapeutics, Inc. | Phase 2 |
| Completed | Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 NCT02307682 | Alcon Research | Phase 3 |
| Completed | Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization NCT02260687 | Bayer | — |
| Completed | Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients NCT01948830 | Novartis Pharmaceuticals | Phase 3 |
| Completed | An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Oc NCT01908816 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD NCT01880788 | Sequenom, Inc. | — |
| Completed | Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study NCT02015351 | University of Sao Paulo | N/A |
| Withdrawn | Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy NCT01666236 | Federal University of São Paulo | Phase 4 |
| Completed | Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome NCT01578720 | Retina Research Institute, LLC | Phase 1 |
| Completed | PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular NCT01445899 | Quark Pharmaceuticals | Phase 2 |
| Unknown | A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye NCT01531842 | Mid Atlantic Retina | N/A |
| Completed | SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia NCT03409250 | Vista Klinik | Phase 4 |
| Completed | Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Deg NCT01334294 | Notal Vision Ltd. | — |
| Completed | Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD NCT03393767 | Vista Klinik | Phase 4 |
| Completed | 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration NCT01175395 | University of Illinois at Chicago | Phase 1 / Phase 2 |
| Withdrawn | Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD NCT01256580 | Massachusetts Eye and Ear Infirmary | N/A |
| Completed | Retinal Therapy Guided by 3D OCT Image Analysis NCT02308215 | Michael Abramoff | — |
| Terminated | Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated NCT01021956 | Steba Biotech S.A. | Phase 2 |
| Completed | Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degener NCT01136252 | Hospital Universitari Vall d'Hebron Research Institute | Phase 2 |
| Unknown | Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot S NCT00855608 | Rafic Hariri University Hospital | Phase 1 |
| Withdrawn | Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Tre NCT00813514 | Medical University of Vienna | N/A |
| Terminated | Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Ag NCT00766337 | Santen Inc. | Phase 2 |
| Completed | Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VE NCT00775411 | Allergan | Phase 2 |
| Terminated | Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degenerati NCT00712491 | Santen Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated NCT00967850 | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | Phase 3 |
| Completed | Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due NCT01628354 | University of Melbourne | Phase 4 |
| Completed | Bevacizumab Effect on Blood Velocity NCT01298440 | Optical Imaging, Ltd. | — |
| Completed | Use of Spectral OCT in Combination Therapy NCT01025063 | Barnes Retina Institute | — |
| Completed | Sensitivity of the Home Macular Perimeter (HMP) NCT00604071 | Notal Vision Ltd. | — |
| Completed | Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti- NCT00511706 | Allergan | Phase 2 |
| Unknown | Stratus Versus Cirrus OCT in AMD NCT00568191 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | — |
| Completed | Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OC NCT01256632 | Vision Research Foundation | N/A |
| Completed | Evaluation of Dosing Interval of Higher Doses of Ranibizumab NCT00533520 | Brandon G. Busbee, MD | Phase 4 |
| Completed | Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) NCT00510965 | University Hospital, Bonn | Phase 2 |
| Completed | Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) NCT00492284 | QLT Inc. | Phase 2 |
| Terminated | Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD NCT00509548 | TargeGen | Phase 2 |
| Completed | EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) NCT00470678 | Novartis | Phase 3 |
| Terminated | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choro NCT00433017 | Novartis | Phase 2 / Phase 3 |
| Completed | Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular NCT00473642 | Oklahoma State University Center for Health Sciences | Phase 4 |
| Completed | Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With NCT00436553 | Novartis | Phase 3 |
| Completed | Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab NCT00417703 | Oklahoma State University Center for Health Sciences | — |
| Completed | Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study) NCT00417846 | Johns Hopkins University | — |
| Completed | Photodynamic and Pharmacologic Treatment of CNV NCT00570193 | Mid-Atlantic Retina Consultations, Inc. | Phase 1 / Phase 2 |
| Completed | Intravitreal Bevacizumab in Agioid Streaks NCT00406250 | University of Campania Luigi Vanvitelli | Phase 1 |
| Withdrawn | Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Seco NCT00403156 | Vitreous -Retina- Macula Consultants of New York | Phase 1 |
| Completed | Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial NCT00363168 | Johns Hopkins University | Phase 1 |
| Completed | Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV NCT00429962 | University Hospital, Basel, Switzerland | Phase 3 |
| Terminated | Efficacy of Retreatments With Intravitreal Bevacizumab NCT00406744 | Asociación para Evitar la Ceguera en México | Phase 3 |
| Completed | Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT) NCT00729846 | California Retina Consultants | Phase 2 |
| Completed | SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Relate NCT00331864 | Novartis | Phase 3 |
| Completed | Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD NCT00426998 | Retinal Consultants Medical Group | Phase 2 |
| Terminated | Macugen for Histoplasmosis NCT00272766 | Barnes Retina Institute | N/A |
| Completed | Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration NCT00304954 | National Eye Institute (NEI) | Phase 2 |
| Terminated | Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment NCT00417833 | Asociación para Evitar la Ceguera en México | Phase 2 / Phase 3 |
| Completed | Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by NCT00395551 | Ophthalmic Consultants of Boston | Phase 1 |
| Completed | A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related M NCT00251459 | Genentech, Inc. | Phase 3 |
| Terminated | Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks NCT00599820 | Asociación para Evitar la Ceguera en México | Phase 3 |
| Completed | Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascula NCT00370786 | Shahid Beheshti University of Medical Sciences | Phase 3 |
| Completed | A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Differ NCT00242580 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular NCT00407719 | Johns Hopkins University | Phase 1 |
| Completed | Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization S NCT01423149 | Mateon Therapeutics | Phase 2 |
| Terminated | Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease NCT00102115 | Light Sciences LLC | Phase 1 |
| Completed | A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovasc NCT00363714 | Allergan | Phase 1 / Phase 2 |
| Unknown | Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System NCT00100087 | Theragenics Corporation | Phase 1 / Phase 2 |
| Unknown | TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration NCT00260403 | St. Erik Eye Hospital | Phase 2 / Phase 3 |
| Completed | Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration NCT01570790 | Johns Hopkins University | Phase 1 / Phase 2 |
| Completed | Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT) NCT00305630 | Johns Hopkins University | Phase 2 / Phase 3 |
| Completed | Phase II/III Study of Anti-VEGF in Neovascular AMD NCT00021736 | Eyetech Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Fluocinolone Implant to Treat Macular Degeneration NCT00008515 | National Eye Institute (NEI) | Phase 1 |
| Completed | Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular D NCT00001615 | National Eye Institute (NEI) | Phase 1 |
| Unknown | Macular Photocoagulation Study (MPS) NCT00000158 | National Eye Institute (NEI) | Phase 3 |
| Withdrawn | Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patie NCT01336907 | Notal Vision Ltd. | — |